Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salanersen in Participants Aged 15-60 Years With Spinal Muscular Atrophy
NCT07444476Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 3 trial of salanersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Sep 2026; status: recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07444476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444476.